Uncovering the Potential of CD40 Agonism to Enhance Immune Checkpoint Blockade

被引：2
|
作者：
Wu, Richard C. [1 ,2 ]
Luke, Jason J. [3 ,4 ]
机构：
[1] Ohio State Univ, James Comprehens Canc Ctr, Columbus, OH 43210 USA
[2] Div Med Oncol, Columbus, OH USA
[3] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[4] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA
来源：
CLINICAL CANCER RESEARCH | 2024年 / 30卷 / 01期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1158/1078-0432.CCR-23-2437
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In this CCR Translations, we discuss the therapeutic potential of CD40 agonism, which stimulates antigen-presenting cells (APC) to activate effector T and NK cells. CD40 agonism may lead to development of an interferon-activated, T cell-inflamed tumor microenvironment and has the potential to facilitate long-term response with immune checkpoint blockade.
引用
收藏
页码：9 / 11
页数：3
相关论文
共 50 条
  • [41] Involvement of CD40 on immune cells in response to immune complexes
    Atsumi, K.
    Matsushima, M.
    Ogiso, H.
    Ochi, H.
    Kusatsugu, Y.
    Oyabu, S.
    Ogasawara, N.
    Takemura, K.
    Kawabe, T.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2016, 46 : 1140 - 1141
  • [42] A combined effect of immune checkpoint inhibitors and a CD40 agonistic antibody in a pancreatic cancer mouse model
    Ichikawa, Juri
    Kawano, Kuniyuki
    Kato, Shingo
    Kurotaki, Daisuke
    Kuroishikawa, Ryo
    Kawase, Wataru
    Yoshida, Haruka
    Hiroshima, Yukihiko
    Endo, Itaru
    Maeda, Shin
    Nakajima, Atsushi
    Tamura, Tomohiko
    CANCER SCIENCE, 2024, 115 : 763 - 763
  • [43] Rationale for CD40 pathway blockade in autoimmune rheumatic disorder
    Pucino, Valentina
    Gardner, David
    Fisher, Benjamin A.
    LANCET RHEUMATOLOGY, 2020, 2 (05): : E292 - E301
  • [44] Costimulation Blockade of CD40 and CD28 Pathways in Limb Transplantation
    Tung, T. H. H.
    Mackinnon, S. E.
    Mohanakurnar, T.
    TRANSPLANTATION PROCEEDINGS, 2008, 40 (10) : 3723 - 3724
  • [45] Potential role of soluble CD40 in the humoral immune response impairment of uraemic patients
    Contin, C
    Pitard, V
    Delmas, Y
    Pelletier, N
    Defrance, T
    Moreau, JF
    Merville, P
    Déchanet-Merville, J
    IMMUNOLOGY, 2003, 110 (01) : 131 - 140
  • [46] Intratumoral CD40 activation and checkpoint blockade induces systemic anti-melanoma immunity that eradicates disseminated tumors
    Singh, Manisha
    Vianden, Christina
    Diab, Adi
    Hwu, Patrick
    Overwijk, Willem W.
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (11)
  • [47] Characteristics of CD40L/CD40 costimulation blockade in prevention of hepatocyte rejection.
    Gao, DH
    Li, JS
    Orosz, CG
    Bumgardner, GL
    TRANSPLANTATION, 2000, 69 (08) : S284 - S284
  • [48] The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer
    Meltzer, Sebastian
    Torgunrud, Annette
    Abrahamsson, Hanna
    Solbakken, Arne Mide
    Flatmark, Kjersti
    Dueland, Svein
    Bakke, Kine Mari
    Bousquet, Paula Anna
    Negard, Anne
    Johansen, Christin
    Lyckander, Lars Gustav
    Larsen, Finn Ole
    Schou, Jakob Vasehus
    Redalen, Kathrine Roe
    Ree, Anne Hansen
    BRITISH JOURNAL OF CANCER, 2021, 125 (02) : 240 - 246
  • [49] The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer
    Sebastian Meltzer
    Annette Torgunrud
    Hanna Abrahamsson
    Arne Mide Solbakken
    Kjersti Flatmark
    Svein Dueland
    Kine Mari Bakke
    Paula Anna Bousquet
    Anne Negård
    Christin Johansen
    Lars Gustav Lyckander
    Finn Ole Larsen
    Jakob Vasehus Schou
    Kathrine Røe Redalen
    Anne Hansen Ree
    British Journal of Cancer, 2021, 125 : 240 - 246
  • [50] Multiprong CD38 targeting to enhance anti-PD1 immune checkpoint blockade efficacy
    Vijayan, Vishnu Vijay
    Nair, Preethi Gopalakrishnan
    Gujar, Shashi
    ONCOIMMUNOLOGY, 2024, 13 (01):
12345